Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012 Japan
info@chordiatherapeutics.com<Press Release>
Jun 7, 2022
Chordia Therapeutics Concludes Basic Agreement on Collaboration
with Shionogi Pharma Co., Ltd.
Kanagawa, Japan, May 19, 2022 – Chordia Therapeutics Inc. (“Chordia”), a biotech
company engaged in the research and development of novel therapies for cancers, today
announced that it signed a basic agreement on collaboration with Shionogi Pharma,Co., Ltd. (“Shionogi Pharma”)
Based on the basic collaboration agreement, Chordia will proceed with specificdiscussions with Shionogi Pharma regarding the production of small-moleculecompounds. Shionogi Pharma has extensive know-how including analytical andAPI formulation manufacturing capabilities in the production of small-moleculecompounds from drug development to the commercial stage. Chordia expects thatcollaborating with Shionogi Pharma on the manufacturing of our oncology pipeline
will promote the development of high-quality small-molecule anti-cancer drugs andcontribute to delivering new treatment options to patients.
About Shionogi Pharma
Shionogi Pharma started its business April 1, 2019 with the mission “to become
contract development and manufacturing organization trusted by our customers.”
Shionogi Pharma can provide “Full-range Services” for development of APIs anddrug products as well as their commercial manufacturing. Shionogi Pharma canalso provide services for developing analytical methods and designing
pharmaceutical facilities based on its pharmaceutical engineering technologies.
Established:
October 2018
Business Description: Manufacture, sales, analysis and testing, and pharmaceuticalengineering of ethical drugs, investigational drugs, veterinary
drugs, etc.
Location:5-1, Mishima 2-chome, Settsu, Osaka 566-0022, Japan
Representative:
Ryuichi Kume, President & CEOWebsite:
https://www.shionogi-ph.co.jp/en/
About Chordia Therapeutics
Chordia was established in November 2017 at Shonan Health Innovation Park(“Shonan iPark”) in Fujisawa, Kanagawa Prefecture, as a biotech company engaged in
the research and development of novel therapies for cancers, with the goal ofresearching and developing first-in-class anti-cancer drugs and creating innovative
new drugs.
The CLK inhibitor CTX-712, which is currently under development as the leadprogram, is currently undergoing Phase I clinical trials in Japan for patients withadvanced, relapsed or refractory malignancies. CTX-712 targets vulnerabilities

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012 Japan
info@chordiatherapeutics.com

resulting from RNA deregulation, which has been identified as a new hallmark ofcancer, and is expected to be an effective therapeutic agent.
In addition to its leading program for CTX-712, Chordia is engaged in the research of
several developments in our pipeline, including CTX-439, a CDK12 inhibitor, whichis expected to be effective in cancers with specific abnormalities, as well as GCN2inhibitors.
Established:
Address:
Representative:
Website:November 2017
26-1, Muraoka-Higashi 2 chome, Fujisawa, Kanagawa 251-0012,
Japan
Hiroshi Miyake, Representative Director
https://www.chordiatherapeutics.com/en/

For more information, contact Kentaro Kume, IR: info@chordiatherapeutics.com